Anadys Pharmaceuticals To Present at the BIO 2003 Annual Convention.

Business Editors/Health/Medical Writers

BIO 2003 Annual Convention

SAN DIEGO--(BUSINESS WIRE)--June 19, 2003

Anadys Pharmaceuticals, Inc. ("Anadys") announced today that it will present at the BIO Business Forum, a part of BIO 2003, on Tuesday June 24, 2003 at 2:00 PM EDT in Room A at the Washington Convention Center, Washington, DC.

Mr. Michael Kamdar, Vice-President, Corporate Development & Strategy for Anadys will provide a corporate overview and present an update on ANA245, which is in Phase IB studies for HCV, as well as Anadys' HCV and antibacterial programs, and partnerships.

"We look forward to the opportunity to highlight our corporate growth strategy to members of the life science investment and partnering community at the BIO Annual Convention, a forum that has for 10 years served as the largest gathering of biotechnology leaders," said Michael Kamdar. "We have carefully executed our business strategy and anticipate building upon our recent accomplishments, which have included a major financing, the signing of important biotech and pharma partnerships, entry into the clinic with our lead hepatitis C compound, and significant progress in our antibacterial programs."

Anadys Pharmaceuticals, Inc. (www.anadyspharma.com) is committed to advancing patient care by discovering, developing and commercializing novel and powerful anti-infective medicines. The company utilizes an integrated drug discovery and development process with world-class expertise in high-output medicinal chemistry that is designed to advance a strong and continual pipeline of drug candidates into the clinic. The Company's primary therapeutic focus encompasses the antiviral and antibacterial market, which represents over $31 billion, with a significant opportunity for novel and improved therapeutics. Anadys has the ability to pursue traditional protein targets as well as underexploited targets including RNA and proteins of unknown function.